SCHEMBL3287645

SCHEMBL3287645

Cc1cccc(C(Cc2cccc(F)c2F)NC(=O)NCCF)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSA P10619 2/20 0.39
CCR3 P51677 1/20 0.37
KMT2A Q03164 1/20 0.37
SLC6A9 P48067 1/20 0.36
SLC6A5 Q9Y345 1/20 0.36
CYP26A1 O43174 1/20 0.35
EPHX2 P34913 2/20 0.34
OPRM1 P35372 2/20 0.34
GAA P10253 1/20 0.34
PIN1 Q13526 1/20 0.34
KCNA5 P22460 1/20 0.34
KCNH2 Q12809 1/20 0.34
KCNB1 Q14721 1/20 0.34
FBP1 P09467 4/20 0.33
RAB9A P51151 1/20 0.33
OPRL1 P41146 1/20 0.33
GPR139 Q6DWJ6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3281456 0.92 KMT2A (0.42) CTSACCR3KMT2ASLC6A9SLC6A5
SCHEMBL3282899 0.86 SLC6A9 (0.40) CTSACCR3KMT2ASLC6A9SLC6A5
SCHEMBL3281878 0.82 CCR3 (0.46) CCR3SLC6A9SLC6A5EPHX2OPRM1
SCHEMBL3281208 0.82 CCR3 (0.57) CCR3KMT2AEPHX2RAB9A
SCHEMBL3285359 0.81 CCR3 (0.46) CCR3KMT2ASLC6A9SLC6A5EPHX2
SCHEMBL3286069 0.79 CCR3 (0.46) CCR3KMT2AEPHX2
SCHEMBL3283121 0.79 CCR3 (0.52) CCR3KMT2AEPHX2GAA
SCHEMBL3282182 0.78 ALDH1A1 (0.40) CCR3KMT2ACYP26A1GAARAB9A
SCHEMBL3285379 0.77 CCR3 (0.41) CCR3OPRM1OPRL1
SCHEMBL3281078 0.77 RAB9A (0.46) CCR3KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2018364-B1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN INC (US) 2013-08-21 EP claimed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US claimed
EP-2018364-A1 THERAPEUTIC FLUOROETHYL UREAS Allergan, Inc. (US) 2009-01-28 EP claimed
WO-2007137029-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. (US) 2007-11-29 WO claimed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US claimed
EP-2018364-B1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN INC (US) 2013-08-21 EP disclosed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US disclosed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US disclosed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US disclosed
EP-2018364-A1 THERAPEUTIC FLUOROETHYL UREAS Allergan, Inc. (US) 2009-01-28 EP disclosed
WO-2007137029-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. (US) 2007-11-29 WO disclosed
WO-2007137029-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. (US) 2007-11-29 WO disclosed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US disclosed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US disclosed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS SLC14A1, MAPT, UTS2R CTSA 894/4885CCR3 4014/4885KMT2A 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.